| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Profit before tax | -8.6 | -4.8 |
| Net income | -8.6 | -4.8 |
| EPS (diluted, $ a share) | $-12.22 | $-98.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PPCB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Propanc Biopharma, Inc.: key numbers
- Share price
- $1.89Close, Nov 16
- Market cap
- $12M
- Shares outstanding
- 6.33MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Propanc Biopharma, Inc.
All →Propanc Biopharma Nasdaq/NYSE Compliance Notice
Propanc Biopharma received a delisting notice from Nasdaq on October 23, 2026, for failing to maintain the $1.00 minimum bid price requirement. Because the company already completed a reverse stock split within the past year, it is ineligible for the standard 180-day grace period and faces delisting on November 2, 2026. The company intends to appeal the determination to a hearings panel, which will stay the delisting process.
- Counterparty
- Nasdaq